

# Maria T Voso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5345984/publications.pdf>

Version: 2024-02-01

254  
papers

8,518  
citations

57681

46  
h-index

75989

78  
g-index

261  
all docs

261  
docs citations

261  
times ranked

9381  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.	3.3	42
2	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. <i>Blood Advances</i> , 2022, 6, 2510-2516.	2.5	3
3	Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation. <i>Chemotherapy</i> , 2022, 67, 24-28.	0.8	0
4	Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. <i>Blood</i> , 2022, 139, 2145-2155.	0.6	38
5	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. <i>Antioxidants</i> , 2022, 11, 113.	2.2	6
6	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. <i>Blood Advances</i> , 2022, 6, 2219-2229.	2.5	40
7	Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey. <i>Frontiers in Oncology</i> , 2022, 12, 828072.	1.3	2
8	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. <i>British Journal of Haematology</i> , 2022, 198, 103-113.	1.2	7
9	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. <i>Blood Advances</i> , 2022, 6, 2207-2218.	2.5	24
10	CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML. <i>Leukemia</i> , 2022, , .	3.3	2
11	Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis. <i>Frontiers in Oncology</i> , 2022, 12, 871590.	1.3	16
12	Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment. <i>Cancers</i> , 2022, 14, 2565.	1.7	12
13	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. <i>Cancers</i> , 2022, 14, 3012.	1.7	0
14	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
15	Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 163-168.	0.6	3
16	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS. <i>Leukemia</i> , 2021, 35, 835-849.	3.3	54
17	Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. <i>British Journal of Haematology</i> , 2021, 193, 129-132.	1.2	17
18	Diagnosis and Classification of AML: WHO 2016. <i>Hematologic Malignancies</i> , 2021, , 23-54.	0.2	1

#	ARTICLE	IF	CITATIONS
19	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. <i>Biology</i> , 2021, 10, 128.	1.3	5
20	Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation. <i>Cancers</i> , 2021, 13, 1083.	1.7	3
21	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	3.3	51
22	What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms. <i>Blood</i> , 2021, 138, 749-757.	0.6	23
23	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	0.8	127
24	Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 385-397.	1.3	7
25	Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 3839-3847.	1.3	9
26	Myeloid lncRNA <i>LOUP</i> mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. <i>Blood</i> , 2021, 138, 1331-1344.	0.6	19
27	Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study. <i>Scientific Reports</i> , 2021, 11, 12762.	1.6	29
28	A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib. <i>Chemotherapy</i> , 2021, 66, 134-138.	0.8	8
29	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.	0.8	2
30	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. <i>Cancers</i> , 2021, 13, 4744.	1.7	9
31	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	2.5	5
32	Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 642.	1.8	12
33	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021, 11, 167.	2.8	11
34	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	5.8	17
35	Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. <i>Blood</i> , 2021, 138, 608-608.	0.6	0
36	What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, , 1-6.	0.9	0

#	ARTICLE	IF	CITATIONS
37	CD34 <sup>+</sup> CD38-CLL1 <sup>+</sup> leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	0.6	1
38	Have we reached a molecular era in myelodysplastic syndromes?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 418-427.	0.9	23
39	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	3.3	46
40	PML/RAR $\alpha$ Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells. <i>Cancers</i> , 2020, 12, 95.	1.7	10
41	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2020, 61, 979-982.	0.6	1
42	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.	0.8	6
43	Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia. <i>Leukemia Research</i> , 2020, 99, 106462.	0.4	4
44	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	2.5	34
45	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	15.2	372
46	Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells. <i>Blood Cancer Journal</i> , 2020, 10, 85.	2.8	9
47	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. <i>Cells</i> , 2020, 9, 2423.	1.8	12
48	Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. <i>Scientific Reports</i> , 2020, 10, 9156.	1.6	9
49	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	0.7	2
50	Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. <i>Cancers</i> , 2020, 12, 1746.	1.7	18
51	Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 256-260.	0.6	1
52	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 357.	1.7	11
53	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	0.6	127
54	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. <i>Blood</i> , 2020, 136, 2-2.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy. <i>Blood</i> , 2020, 136, 19-20.	0.6	1
56	<scp>PML</scp>/<scp>RARA</scp> inhibits expression of <scp>HSP</scp>90 and its target <scp>AKT</scp>. <i>British Journal of Haematology</i> , 2019, 184, 937-948.	1.2	11
57	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. <i>American Journal of Hematology</i> , 2019, 94, 1091-1097.	2.0	25
58	MRD in AML: The Role of New Techniques. <i>Frontiers in Oncology</i> , 2019, 9, 655.	1.3	93
59	Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies. <i>Cancers</i> , 2019, 11, 1591.	1.7	70
60	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.	0.6	148
61	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. <i>Cancers</i> , 2019, 11, 1373.	1.7	13
62	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. <i>Leukemia Research</i> , 2019, 84, 106191.	0.4	5
63	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 865.	1.7	22
64	Treatment of Philadelphiaâ€negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019, 37, 291-295.	0.8	14
65	Could haemochromatosis (<i><scp>HFE</scp></i>) gene mutations affect response to iron chelation in myelodysplastic syndrome? â€ Response to Lucijanac and Kusec. <i>British Journal of Haematology</i> , 2019, 186, 639-640.	1.2	1
66	Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. <i>British Journal of Haematology</i> , 2019, 186, e100-e103.	1.2	2
67	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. <i>Biochemical Pharmacology</i> , 2019, 167, 133-148.	2.0	19
68	When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia. <i>Chemotherapy</i> , 2019, 64, 238-247.	0.8	19
69	Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML. <i>Blood Advances</i> , 2019, 3, 4155-4160.	2.5	22
70	Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (<scp>MDS</scp>). <i>British Journal of Haematology</i> , 2019, 185, 954-957.	1.2	4
71	Identification and monitoring of atypicalPML/RARafusion transcripts in acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 60-65.	1.5	14
72	The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. <i>Haematologica</i> , 2019, 104, 973-985.	1.7	31

#	ARTICLE	IF	CITATIONS
73	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1527-1530.	3.3	16
74	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019, 34, 16-25.	2.8	15
75	Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. <i>Leukemia</i> , 2019, 33, 785-790.	3.3	33
76	Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 307-313.	1.0	21
77	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018, 55, 209-214.	1.8	39
78	Longitudinal detection of DNMT3A <sup>R882H</sup> transcripts in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E120-E123.	2.0	7
79	The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF- $\kappa$ B activation. <i>Cancer Letters</i> , 2018, 423, 127-138.	3.2	22
80	Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 1268-1270.	0.6	1
81	MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. <i>Pharmacogenomics Journal</i> , 2018, 18, 444-449.	0.9	2
82	Molecular Expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinase plasma cellular disorders: a molecular panel to investigate disease progression. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2018, 10, e2018059.	0.5	5
83	Therapy-related myeloid neoplasms: clinical perspectives. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5909-5915.	1.0	12
84	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018, 97, 1797-1802.	0.8	20
85	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 89-91.	0.4	2
86	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 1767-1774.	0.8	15
87	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. <i>Lancet Haematology</i> , 2017, 4, e127-e136.	2.2	132
88	Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017, 177, 741-750.	1.2	23
89	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	3.3	51
90	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <i>Annals of Oncology</i> , 2017, 28, 1547-1553.	0.6	46

#	ARTICLE	IF	CITATIONS
91	Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2017, 52, 473-475.	1.3	21
92	Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. <i>Leukemia Research</i> , 2017, 62, 108-115.	0.4	25
93	The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia. <i>Oncotarget</i> , 2017, 8, 84074-84085.	0.8	4
94	Clonal evolution in therapy-related neoplasms. <i>Oncotarget</i> , 2017, 8, 12031-12040.	0.8	22
95	High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts <i>in vitro</i> . <i>Oncotarget</i> , 2017, 8, 32550-32565.	0.8	47
96	Progress and criticalities in the management of acute promyelocytic leukemia. <i>Oncotarget</i> , 2017, 8, 99221-99222.	0.8	8
97	Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. <i>BMJ Supportive and Palliative Care</i> , 2016, 6, 80-88.	0.8	16
98	A POPULATION-BASED STUDY ON MYELOYDYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017046.	0.5	3
99	MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016052.	0.5	18
100	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. <i>Future Oncology</i> , 2016, 12, 293-302.	1.1	36
101	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016, 96, 344-351.	1.1	31
102	Mutations affecting both the rearranged and the unrearranged <i>PML</i> alleles in refractory acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 909-913.	1.2	23
103	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. <i>BMC Hematology</i> , 2016, 16, 12.	2.6	31
104	<i>PML</i> kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. <i>Leukemia</i> , 2016, 30, 1987-1992.	3.3	75
105	Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a Gruppo Romano Mielodisplasie (GROM) multicenter study. <i>Annals of Hematology</i> , 2016, 95, 1059-1065.	0.8	7
106	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	0.8	204
107	Panobinostat for the treatment of acute myelogenous leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1117-1131.	1.9	23
108	CD 68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. <i>Cancer Medicine</i> , 2016, 5, 398-406.	1.3	28

#	ARTICLE	IF	CITATIONS
109	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 972-979.	0.8	296
110	Impairment of PI3K/AKT and WNT/ $\beta$ -catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. <i>Experimental Hematology</i> , 2016, 44, 75-83.e4.	0.2	42
111	Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 628-634.	0.6	24
112	PML/RAR $\alpha$ inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity. <i>Oncotarget</i> , 2016, 7, 66386-66397.	0.8	19
113	Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2015, 27, 532-539.	1.1	19
114	Four doses of unpegylated <i>versus</i> one dose of pegylated filgrastim as supportive therapy in R $\alpha$ -CHOP $\alpha$ 14 for elderly patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 787-794.	1.2	10
115	Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. <i>Leukemia Research</i> , 2015, 39, 801-804.	0.4	25
116	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	2.0	93
117	Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia. <i>Neoplasia</i> , 2015, 17, 401-409.	2.3	24
118	An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. <i>Annals of Hematology</i> , 2015, 94, 771-777.	0.8	25
119	Deferasirox chelation therapy in patients with transfusion-dependent MDS: a "real-world" report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. <i>European Journal of Haematology</i> , 2015, 95, 52-56.	1.1	22
120	Fanconi anemia gene variants in therapy-related myeloid neoplasms. <i>Blood Cancer Journal</i> , 2015, 5, e323-e323.	2.8	32
121	Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin. <i>British Journal of Haematology</i> , 2015, 168, 617-617.	1.2	9
122	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	5.1	76
123	An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome. <i>Blood Cancer Journal</i> , 2015, 5, e370-e370.	2.8	0
124	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 859-865.	0.4	17
125	Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 85-89.	1.2	1
126	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. <i>Leukemia</i> , 2014, 28, 621-628.	3.3	80



#	ARTICLE	IF	CITATIONS
127	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 2942-2944.	0.6	4
128	Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders. <i>American Journal of Hematology</i> , 2014, 89, 346-347.	2.0	2
129	Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). <i>European Journal of Haematology</i> , 2014, 92, 527-536.	1.1	90
130	The <i>BCL2L10</i> Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2014, 55, 1538-1543.	0.6	22
131	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014, 25, 447-454.	0.6	38
132	Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 467-476.	1.2	16
133	Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. <i>Annals of Hematology</i> , 2014, 93, 1413-1420.	0.8	7
134	Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014, 89, 565-565.	2.0	2
135	Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. <i>Leukemia and Lymphoma</i> , 2014, 55, 270-275.	0.6	43
136	Why methylation is not a marker predictive of response to hypomethylating agents. <i>Haematologica</i> , 2014, 99, 613-619.	1.7	61
137	Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies. <i>Experimental Hematology</i> , 2014, 42, 731-733.	0.2	4
138	Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy. <i>OncoTargets and Therapy</i> , 2014, 7, 1043.	1.0	9
139	SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. <i>Haematologica</i> , 2014, 99, e152-e153.	1.7	16
140	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013, 54, 1786-1787.	0.6	8
141	Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far?. <i>Leukemia Research</i> , 2013, 37, 204-205.	0.4	6
142	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 345-348.	1.1	37
143	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 658-661.	0.6	54
144	Small lymphocytic lymphoma in a patient with Fabry disease. <i>Leukemia and Lymphoma</i> , 2013, 54, 184-185.	0.6	6

#	ARTICLE	IF	CITATIONS
145	Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. <i>Leukemia</i> , 2013, 27, 982-985.	3.3	22
146	Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2671-2677.	0.8	121
147	Iron in Hodgkin's Lymphoma. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 463-469.	0.2	5
148	Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. <i>Blood</i> , 2013, 122, 5229-5229.	0.6	0
149	Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials. <i>Blood</i> , 2013, 122, 5203-5203.	0.6	0
150	Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 805-807.	0.6	12
151	Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: results from the hd2000 GISL trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 406-410.	0.6	3
152	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012, 5, 44.	6.9	49
153	Myelodysplastic Stem Cells: Gene Expression Profiling. <i>Stem Cells and Cancer Stem Cells</i> , 2012, , 55-67.	0.1	0
154	Interleukin-6 plasma levels are modulated by a polymorphism in the $\text{NF-}\hat{\text{B}}1$ gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 411-416.	0.6	36
155	Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule. <i>Leukemia Research</i> , 2012, 36, e15-e17.	0.4	3
156	Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 474-478.	0.4	15
157	Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. <i>Leukemia Research</i> , 2012, 36, 331-333.	0.4	28
158	Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience. <i>Blood</i> , 2012, 120, 4958-4958.	0.6	0
159	The Contact with MDS Endothelial Cells Alters the Pattern of Lineage-Specific Gene Expression During Normal Hematopoietic Differentiation. <i>Blood</i> , 2012, 120, 1718-1718.	0.6	0
160	Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients. <i>Blood</i> , 2012, 120, 4951-4951.	0.6	0
161	Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. <i>Blood</i> , 2012, 120, 3163-3163.	0.6	0
162	5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011011.	0.5	5

#	ARTICLE	IF	CITATIONS
163	Therapy-related myeloid neoplasms. <i>Current Opinion in Oncology</i> , 2011, 23, 672-680.	1.1	49
164	Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2011, 154, 141-143.	1.2	6
165	Primary plasma cell leukemia followed by testicular plasmacytoma. <i>International Journal of Hematology</i> , 2011, 93, 224-227.	0.7	7
166	Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. <i>Leukemia Research</i> , 2011, 35, 465-471.	0.4	11
167	The Viral Load of Epstein-Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2011, 17, 2885-2892.	3.2	89
168	Reply to S. Zucker. <i>Journal of Clinical Oncology</i> , 2011, 29, e43-e43.	0.8	0
169	Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. <i>Leukemia</i> , 2011, 25, 1910-1913.	3.3	40
170	INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011069.	0.5	24
171	Risk of acute promyelocytic leukemia in multiple sclerosis. <i>Neurology</i> , 2011, 76, 1059-1065.	1.5	37
172	SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011052.	0.5	8
173	Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 2078-2078.	0.6	0
174	Epigenetic changes in therapy-related MDS/AML. <i>Chemico-Biological Interactions</i> , 2010, 184, 46-49.	1.7	36
175	Incidence and susceptibility to therapy-related myeloid neoplasms. <i>Chemico-Biological Interactions</i> , 2010, 184, 39-45.	1.7	85
176	Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies. <i>Mycoses</i> , 2010, 53, 89-92.	1.8	8
177	NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010021.	0.5	4
178	Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy. <i>Bone Marrow Transplantation</i> , 2010, 45, 1668-1670.	1.3	14
179	Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hcpidin. <i>Journal of Clinical Oncology</i> , 2010, 28, 2538-2543.	0.8	86
180	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 181-185.	0.6	28

#	ARTICLE	IF	CITATIONS
181	Analysis of genome-wide methylation and gene expression induced by 5-aza-2â€²-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 2275-2284.	0.6	43
182	Quantitation of EBV-DNA In Peripheral Blood In Hodgkin Lymphoma: Associations with Other Biomarkers and Patient Characteristics. <i>Blood</i> , 2010, 116, 2678-2678.	0.6	0
183	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2009, 15, 5002-5007.	3.2	103
184	Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2009, 20, 1408-1413.	0.6	110
185	Polymorphisms of detoxification and DNA repair enzymes in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, 1068-1071.	0.4	23
186	Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. <i>Leukemia Research</i> , 2009, 33, 1352-1356.	0.4	31
187	Combined Voriconazole Plus Caspofungin Therapy for the Treatment of Probable Geotrichum Pneumonia in a Leukemia Patient. <i>Infection</i> , 2008, 36, 65-67.	2.3	24
188	PU.1 and CEBPA expression in acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 1448-1453.	0.4	16
189	Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. <i>Leukemia</i> , 2008, 22, 1685-1691.	3.3	36
190	Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias. <i>Current Medicinal Chemistry</i> , 2008, 15, 1274-1287.	1.2	42
191	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , The, 2008, 9, 352-358.	5.1	80
192	Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. <i>Annals of Oncology</i> , 2008, 19, 128-134.	0.6	30
193	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. <i>Blood</i> , 2008, 112, 3383-3390.	0.6	74
194	5-Azacytidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial. <i>Blood</i> , 2008, 112, 3648-3648.	0.6	1
195	Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 564-569.	0.6	14
196	Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , 2007, 18, 346-350.	0.6	111
197	Therapy-related leukemia and myelodysplasia: susceptibility and incidence. <i>Haematologica</i> , 2007, 92, 1389-1398.	1.7	184
198	Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. <i>Annals of Oncology</i> , 2007, 18, 1523-1528.	0.6	61

#	ARTICLE	IF	CITATIONS
199	CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer-binding protein alpha. <i>Blood</i> , 2007, 110, 3695-3705.	0.6	50
200	Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2007, 18, 1376-1381.	0.6	47
201	P025 Dap-kinase hypermethylation and apoptosis in myelodysplastic syndromes. <i>Leukemia Research</i> , 2007, 31, S54.	0.4	0
202	Blastoid Mantle Cell Lymphoma Occurring in a Patient in Complete Remission of Chronic Myelogenous Leukemia. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2007, 13, 30-33.	1.2	3
203	Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2006, 4, 33-52.	0.4	12
204	Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. <i>British Journal of Cancer</i> , 2006, 95, 1108-1113.	2.9	69
205	Nongastric Marginal Zone Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. <i>Oncologist</i> , 2006, 11, 285-291.	1.9	63
206	A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.. <i>Blood</i> , 2006, 108, 2479-2479.	0.6	4
207	DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. <i>Haematologica</i> , 2006, 91, 1252-6.	1.7	10
208	Profile of azacitidine. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 717-731.	0.2	2
209	Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2005, 11, 2175-2179.	3.2	77
210	Polymorphism in Cytokine Genes as Prognostic Marker in Hodgkin's Lymphoma.. <i>Blood</i> , 2005, 106, 21-21.	0.6	2
211	Gentuzumab-Ozogamicin, Cytosine Arabinoside, G-CSF Combination in the Treatment of Elderly Poor Prognosis Acute Myeloid Leukemia. A Multicentric Study.. <i>Blood</i> , 2005, 106, 4604-4604.	0.6	1
212	Profile of azacitidine. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 717-731.	0.2	1
213	Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials. <i>Leukemia</i> , 2004, 18, 651-653.	3.3	3
214	Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN- $\gamma$ . <i>European Journal of Immunology</i> , 2004, 34, 1291-1302.	1.6	120
215	Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. <i>Blood</i> , 2004, 103, 698-700.	0.6	79
216	In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gentuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study. <i>Haematologica</i> , 2004, 89, 634-6.	1.7	16

#	ARTICLE	IF	CITATIONS
217	Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. <i>Haematologica</i> , 2004, 89, 664-70.	1.7	46
218	Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. <i>Clinical Immunology</i> , 2003, 109, 89-102.	1.4	93
219	Letter to the Editor. <i>Leukemia and Lymphoma</i> , 2003, 44, 1441-1443.	0.6	7
220	Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome after bupropion treatment for smoking cessation. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 77-78.	0.5	3
221	Identification of a Novel Subpopulation of Human Cord Blood CD34 <sup>+</sup> CD133 <sup>+</sup> CD7 <sup>+</sup> CD45 <sup>+</sup> Lineage <sup>-</sup> Cells Capable of Lymphoid/NK Cell Differentiation After In Vitro Exposure to IL-15. <i>Journal of Immunology</i> , 2003, 171, 2977-2988.	0.4	42
222	Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. <i>Clinical Cancer Research</i> , 2003, 9, 3435-40.	3.2	43
223	Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2703-2707.	0.6	110
224	Therapy Related Leukemias: Susceptibility, Prevention and Treatment. <i>Leukemia and Lymphoma</i> , 2001, 41, 255-276.	0.6	115
225	Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jka after allogeneic PBPC transplantation. <i>Transfusion</i> , 2000, 40, 632-636.	0.8	49
226	In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2000, 109, 729-735.	1.2	80
227	Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). <i>Bone Marrow Transplantation</i> , 2000, 25, 957-964.	1.3	46
228	High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors. <i>Annals of Hematology</i> , 2000, 79, 547-555.	0.8	5
229	Microchimerism in bone marrow-derived CD34 <sup>+</sup> cells of patients after liver transplantation. <i>Blood</i> , 2000, 96, 763-767.	0.6	26
230	Autografting with CD34 <sup>+</sup> peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. <i>British Journal of Haematology</i> , 1999, 104, 382-391.	1.2	40
231	Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, S13-S17.	1.1	4
232	The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34 <sup>+</sup> haemopoietic progenitor cells during marrow recovery. <i>British Journal of Haematology</i> , 1998, 101, 588-591.	1.2	19
233	Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor. <i>Gene</i> , 1998, 207, 209-218.	1.0	13
234	Prevalence of the 677C to T Mutation in the Methylenetetrahydrofolate Reductase Gene in Italian Patients with Venous Thrombotic Disease. <i>Thrombosis and Haemostasis</i> , 1998, 79, 686-687.	1.8	16

#	ARTICLE	IF	CITATIONS
235	Mobilization and Selection of CD 34+ Cells. Recent Results in Cancer Research, 1998, , 1-7.	1.8	2
236	The Growth of Primary Low-Grade B-Cell Gastric Lymphoma Is Sustained by <i>Helicobacter pylori</i> . Scandinavian Journal of Gastroenterology, 1997, 32, 285-287.	0.6	27
237	Lack of t(14; 18) Polymerase Chain Reaction-Positive Cells in Highly Purified CD34+ Cells and Their CD19 Subsets in Patients With Follicular Lymphoma. Blood, 1997, 89, 3763-3768.	0.6	27
238	Immunomagnetic selection of CD34 + peripheral blood stem cells for autografting in patients with breast cancer. British Journal of Haematology, 1997, 97, 881-888.	1.2	51
239	Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: Role of heat-shock protein-70. , 1997, 73, 75-83.		32
240	Prevalence of Mutated Factor V ARG506 to GLN in Italians. Thrombosis and Haemostasis, 1997, 77, 216-217.	1.8	5
241	Lack of t(14; 18) Polymerase Chain Reaction-Positive Cells in Highly Purified CD34+ Cells and Their CD19 Subsets in Patients With Follicular Lymphoma. Blood, 1997, 89, 3763-3768.	0.6	1
242	Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma. Blood, 1997, 89, 3763-8.	0.6	2
243	HIGH-DOSE THERAPY WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION RESULTS IN A SIGNIFICANT REDUCTION OF THE HAEMOPOIETIC PROGENITOR CELL COMPARTMENT. British Journal of Haematology, 1996, 94, 759-766.	1.2	10
244	Function of PU.1 (Spi-1), C/EBP, and AML1 in Early Myelopoiesis: Regulation of Multiple Myeloid CSF Receptor Promoters. Current Topics in Microbiology and Immunology, 1996, 211, 137-147.	0.7	111
245	PU.1 (Spi-1) and C/EBP $\beta$ Regulate Expression of the Granulocyte-Macrophage Colony-Stimulating Factor Receptor $\beta$ Gene. Molecular and Cellular Biology, 1995, 15, 5830-5845.	1.1	271
246	Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood, 1995, 85, 2918-2928.	0.6	212
247	Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood, 1995, 85, 2918-28.	0.6	71
248	Prevalence of obesity in young adults with acute lymphoblastic leukemia. International Journal of Clinical and Laboratory Research, 1994, 24, 117-119.	1.0	5
249	Inhibition of hematopoiesis by competitive binding of transcription factor PU.1.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7932-7936.	3.3	142
250	L-Asparaginase-Induced Coagulopathy in Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 1992, 7, 54-56.	0.6	2
251	Hepato-Splenic Mycotic Abscesses in Patients with Acute Leukemia. Leukemia and Lymphoma, 1992, 7, 517-519.	0.6	1
252	DISAPPEARANCE OF SPONTANEOUS ERYTHROID COLONIES IN PATIENTS WITH MYELOPROLIFERATIVE DISORDERS TREATED BY ALPHA-INTERFERON. British Journal of Haematology, 1992, 81, 310-311.	1.2	3

#	ARTICLE	IF	CITATIONS
253	The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression. <i>International Journal of Oncology</i> , 1992, , .	1.4	3
254	Vitamin C Deficiency in Patients With Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4